<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03263390</url>
  </required_header>
  <id_info>
    <org_study_id>170097</org_study_id>
    <nct_id>NCT03263390</nct_id>
  </id_info>
  <brief_title>Modeling the Neurological Basis and Characterizing the Neurological Phenotype of Obesity Using Human Neural Stem Cells</brief_title>
  <official_title>Modeling the Neurological Basis and Characterizing the Neurological Phenotype of Obesity Using Human Neural Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to characterize the neurological basis of obesity and response to surgical&#xD;
      and medical treatment by inducing adult pluripotent stem cells into neuronal cells from&#xD;
      subjects that have demonstrated extreme response to bariatric surgery or pharmacological&#xD;
      treatment for obesity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will consent subjects who have achieved extreme response to either&#xD;
      bariatric surgery or pharmacologic treatment for obesity and harvest fibroblasts from skin&#xD;
      biopsies, which will be reprogrammed to induced pluripotent stem cells (iPSC). These iPSC's&#xD;
      will then be differentiated into neural progenitor cells, neurons, astrocytes, and microglia&#xD;
      to identify genetic and epigenetic pathways altered in disease-specific neural progenitor&#xD;
      cells of the brain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated by study partners&#xD;
  </why_stopped>
  <start_date type="Actual">October 5, 2017</start_date>
  <completion_date type="Actual">August 10, 2020</completion_date>
  <primary_completion_date type="Actual">August 10, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DNA sequencing</measure>
    <time_frame>4 months</time_frame>
    <description>Perform DNA sequencing from skin biopsy progenitor cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Generate human cell based models of obesity</measure>
    <time_frame>4 months</time_frame>
    <description>Fibroblasts will be expanded in culture and then reprogrammed to hiPSCs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differentiation to human CNS cells</measure>
    <time_frame>4 months</time_frame>
    <description>Disease specific hiPSCs cells will be differentiated into neural progenitor cells, neurons, astrocytes, and microglia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of genetic and epigenetic pathways</measure>
    <time_frame>4 months</time_frame>
    <description>Identify genetic and epigenetic pathways altered in disease-specific neural progenitor cells, neurons, and non-neuronal cells of the brain</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">6</enrollment>
  <condition>Obesity, Morbid</condition>
  <arm_group>
    <arm_group_label>Bariatric Surgery</arm_group_label>
    <description>Subjects that have demonstrated extreme response to bariatric surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti Obesity Medications</arm_group_label>
    <description>Subjects that have demonstrated extreme response to anti obesity pharmacotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric Surgery</intervention_name>
    <description>Sleeve gastrectomy or Roux-en-Y Gastric Bypass</description>
    <arm_group_label>Bariatric Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti Obesity Drugs</intervention_name>
    <description>Response to FDA approved anti obesity medications</description>
    <arm_group_label>Anti Obesity Medications</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fibroblasts, iPSCs, and DNA sequencing information generated from skin biopsies will be&#xD;
      expanded and stored for potential future use.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with obesity who are considered super responders to bariatric surgery or anti&#xD;
        obesity pharmacotherapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of obesity&#xD;
&#xD;
          -  Treatment with bariatric surgery&#xD;
&#xD;
          -  Treatment with anti obesity medications&#xD;
&#xD;
          -  Greater than 70% excess weight loss at least 6 months after surgery&#xD;
&#xD;
          -  Greater than 15% weight loss on anti obesity medications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active cancer, not including non-melanoma skin cancer&#xD;
&#xD;
          -  Active eating disorder&#xD;
&#xD;
          -  Use of anti obesity medications in subjects with a history of bariatric surgery&#xD;
&#xD;
          -  Active complication of the upper GI tract in patients with a history of bariatric&#xD;
             surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Grunvald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 24, 2017</study_first_submitted>
  <study_first_submitted_qc>August 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2017</study_first_posted>
  <last_update_submitted>December 12, 2020</last_update_submitted>
  <last_update_submitted_qc>December 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Eduardo Grunvald</investigator_full_name>
    <investigator_title>Clinical Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Bariatric Surgery</keyword>
  <keyword>Anti Obesity Medications</keyword>
  <keyword>Weight Regulation</keyword>
  <keyword>Pluripotent Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Obesity Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is not an intervention trial</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

